Werewolf Therapeutics, Inc. (HOWL)
NASDAQ: HOWL · IEX Real-Time Price · USD
5.87
+0.03 (0.51%)
Apr 18, 2024, 4:00 PM EDT - Market closed
Werewolf Therapeutics Stock Forecast
Stock Price Forecast
The 5 analysts with 12-month price forecasts for HOWL stock have an average target of 10.86, with a low estimate of 8.30 and a high estimate of 15. The average target predicts an increase of 85.01% from the current stock price of 5.87.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for HOWL stock from 5 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '23 | Dec '23 | Jan '24 | Feb '24 | Mar '24 | Apr '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Buy | 1 | 1 | 1 | 1 | 1 | 2 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 4 | 4 | 4 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| JMP Securities | JMP Securities | Buy Initiates $12 | Buy | Initiates | $12 | +104.43% | Apr 3, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $15 | Strong Buy | Maintains | $15 | +155.54% | Mar 7, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $15 | Strong Buy | Reiterates | $15 | +155.54% | Nov 15, 2023 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $15 | Strong Buy | Reiterates | $15 | +155.54% | Oct 31, 2023 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $15 | Strong Buy | Reiterates | $15 | +155.54% | Sep 19, 2023 |
Financial Forecast
Revenue This Year
5.95M
from 19.94M
Decreased by -70.18%
Revenue Next Year
15.78M
from 5.95M
Increased by 165.38%
EPS This Year
-1.34
from -1.05
EPS Next Year
-1.27
from -1.34
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 21.0M | 52.5M | 52.5M | 26.1M | 101.6M |
| Avg | 5.9M | 15.8M | 17.0M | 10.9M | 66.8M |
| Low | n/a | n/a | n/a | n/a | 44.8M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 5.3% | 782.8% | 232.7% | 53.8% | 831.1% |
| Avg | -70.2% | 165.4% | 7.7% | -35.8% | 512.1% |
| Low | - | - | - | - | 310.4% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -1.23 | -0.82 | -1.06 | -1.90 | -1.39 |
| Avg | -1.34 | -1.27 | -1.37 | -1.85 | -1.35 |
| Low | -1.66 | -1.93 | -1.61 | -1.77 | -1.29 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | - | - |
| Avg | - | - | - | - | - |
| Low | - | - | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.